January 27, 2023

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines…

January 19, 2023

Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel

TOKYO, Jan 19, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai…

November 7, 2022

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

TOKYO, Nov 7, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its…

October 4, 2022

Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan

TOKYO, Oct 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced that, as part of the strategic investment towards the realization of…

August 9, 2022

Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care

TOKYO, Aug 9, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a…

July 26, 2022

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

TOKYO, Jul 26, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co. Ltd announced today that the company will present research from its Alzheimer’s disease…

April 1, 2022

Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business

TOKYO, Apr 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued…

March 15, 2022

Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen

TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer’s disease…

March 15, 2022

Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments

CAMBRIDGE, Mass., and TOKYO, Mar 15, 2022 – (JCN Newswire via SEAPRWire.com) – Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the…

March 4, 2022

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to…

January 6, 2022

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

TOKYO, Jan 6, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the…

September 14, 2021

Eisai to Join The Global Environmental Initiative “RE100”

TOKYO, Sep 14, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has joined “RE100”, the global environmental initiative that…

August 31, 2021

Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

TOKYO, Aug 31, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that they have concluded a…

June 18, 2021

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

Tokyo and New York, Jun 18, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that…

June 15, 2021

Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

TOKYO, Jun 15, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its…

May 11, 2021

Eisai’s Statement of Commitment for Carbon Neutrality by 2040

TOKYO, May 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has pledged to reduce greenhouse gas (GHG) emission…

March 31, 2021

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

TOKYO, Mar 31, 2021 – (JCN Newswire via SEAPRWire.com) – KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have…

March 22, 2021

Eisai Awarded The New Diversity Management Selection 100

TOKYO, Mar 22, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it was selected as one of winners of the…

November 18, 2020

Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan

TOKYO, Nov 18, 2020 – (JCN Newswire) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100…